î
îŒ
î
Scinai Immunotherapeutics Ltd
SCNI0.750USD
-0.012-1.57%
çµå€Â 12/24, 13:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
1.14Mæ䟡ç·é¡
0.07çŽè¿12ã¶æPER
î
詳现æ å ± Scinai Immunotherapeutics Ltd äŒæ¥å
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Companyâs core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Scinai Immunotherapeutics Ltdã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãSCNI
äŒç€ŸåScinai Immunotherapeutics Ltd
äžå Žæ¥Jun 07, 2007
æé«çµå¶è²¬ä»»è
ãCEOãReichman (Amir)
åŸæ¥å¡æ°31
蚌åžçš®é¡Depository Receipt
決ç®ææ«Jun 07
æ¬ç€Ÿæåšå°Jerusalem Biopark, 2Nd Floor
éœåžJERUSALEM
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœIsrael
éµäŸ¿çªå·00000
é»è©±çªå·97289302529
ãŠã§ããµã€ãhttps://www.scinai.com/
äŒæ¥ã³ãŒãSCNI
äžå Žæ¥Jun 07, 2007
æé«çµå¶è²¬ä»»è
ãCEOãReichman (Amir)
Scinai Immunotherapeutics Ltdã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+236.54%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
+51.52%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-26.47%
Dr. Yael Margolin
Dr. Yael Margolin
External Director
External Director
50.00
+51.52%
Mr. Samuel J. Moed
Mr. Samuel J. Moed
Director
Director
--
--
Mr. Joshua Phillipson
Mr. Joshua Phillipson
Investor Relations
Investor Relations
--
--
Dr. Morris C. Laster, M.D.
Dr. Morris C. Laster, M.D.
Independent Director
Independent Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+236.54%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
+51.52%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-26.47%
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Sun, Nov 23
æŽæ°æå»: Sun, Nov 23
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
RK Stone Miami, LLC
5.77%
LCK JNK 1 LLC
2.33%
Stone (Daniel E)
1.85%
Armistice Capital LLC
1.29%
Abalone Asset Management Ltd.
1.23%
ä»ã®
87.54%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
RK Stone Miami, LLC
5.77%
LCK JNK 1 LLC
2.33%
Stone (Daniel E)
1.85%
Armistice Capital LLC
1.29%
Abalone Asset Management Ltd.
1.23%
ä»ã®
87.54%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Corporation
8.10%
Hedge Fund
2.54%
Individual Investor
2.20%
Investment Advisor
1.36%
Investment Advisor/Hedge Fund
0.84%
ä»ã®
84.96%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
20
247.18K
7.75%
+209.10K
2025Q2
33
391.87K
45.94%
+279.77K
2025Q1
34
424.61K
49.78%
+268.71K
2024Q4
29
225.02K
26.38%
+113.05K
2024Q3
33
172.68K
20.39%
+41.77K
2024Q2
34
145.50K
9.79%
-4.50K
2024Q1
37
164.38K
100.97%
+8.82K
2023Q4
39
169.63K
48.24%
+28.24K
2023Q3
42
134.35K
45.97%
+54.60K
2023Q2
41
94.79K
37.87%
-787.00
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
LCK JNK 1 LLC
80.76K
2.53%
+80.76K
--
Feb 09, 2025
Stone (Daniel E)
264.20K
8.29%
+201.80K
+323.40%
Sep 29, 2025
Armistice Capital LLC
44.80K
1.41%
+44.80K
--
Sep 30, 2024
Abalone Asset Management Ltd.
42.54K
1.33%
+24.54K
+136.35%
Jun 30, 2024
Sabby Management, LLC
29.05K
0.91%
+29.05K
--
Dec 31, 2024
Citadel Advisors LLC
11.60K
0.36%
+11.60K
--
Jun 30, 2025
Reichman (Amir)
8.08K
0.25%
+5.68K
+236.54%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
3.48K
0.11%
+1.92K
+122.27%
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
SPDR Portfolio Developed World ex-US ETF
0%
SPDR Portfolio Developed World ex-US ETF
æ¯ç0%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
May 06, 2024
Merger
10â1
May 06, 2024
Merger
10â1
May 06, 2024
Merger
10â1
May 06, 2024
Merger
10â1
Nov 23, 2022
Merger
10â1
Nov 23, 2022
Merger
10â1
æ¥ä»
çš®é¡
æ¯ç
May 06, 2024
Merger
10â1
May 06, 2024
Merger
10â1
May 06, 2024
Merger
10â1
May 06, 2024
Merger
10â1
Nov 23, 2022
Merger
10â1
Nov 23, 2022
Merger
10â1
Nov 23, 2022
Merger
10â1
Nov 23, 2022
Merger
10â1
ãããã質å
Scinai Immunotherapeutics Ltdã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îScinai Immunotherapeutics Ltdã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
LCK JNK 1 LLCã¯80.76Kæ ªãä¿æããŠãããããã¯å šäœã®2.53%ã«çžåœããŸãã
Stone (Daniel E)ã¯264.20Kæ ªãä¿æããŠãããããã¯å šäœã®8.29%ã«çžåœããŸãã
Armistice Capital LLCã¯44.80Kæ ªãä¿æããŠãããããã¯å šäœã®1.41%ã«çžåœããŸãã
Abalone Asset Management Ltd.ã¯42.54Kæ ªãä¿æããŠãããããã¯å šäœã®1.33%ã«çžåœããŸãã
Sabby Management, LLCã¯29.05Kæ ªãä¿æããŠãããããã¯å šäœã®0.91%ã«çžåœããŸãã
LCK JNK 1 LLCã¯80.76Kæ ªãä¿æããŠãããããã¯å šäœã®2.53%ã«çžåœããŸãã
Stone (Daniel E)ã¯264.20Kæ ªãä¿æããŠãããããã¯å šäœã®8.29%ã«çžåœããŸãã
Armistice Capital LLCã¯44.80Kæ ªãä¿æããŠãããããã¯å šäœã®1.41%ã«çžåœããŸãã
Abalone Asset Management Ltd.ã¯42.54Kæ ªãä¿æããŠãããããã¯å šäœã®1.33%ã«çžåœããŸãã
Sabby Management, LLCã¯29.05Kæ ªãä¿æããŠãããããã¯å šäœã®0.91%ã«çžåœããŸãã
Scinai Immunotherapeutics Ltdã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îScinai Immunotherapeutics Ltdã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
RK Stone Miami, LLC
LCK JNK 1 LLC
Stone (Daniel E)
RK Stone Miami, LLC
LCK JNK 1 LLC
Stone (Daniel E)
Scinai Immunotherapeutics LtdïŒSCNIïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãScinai Immunotherapeutics Ltdã®æ ªåŒãä¿æããŠããæ©é¢ã¯20瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ247.18Kã§ãå
šäœã®7.75%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-38.19%å¢å ããŠããŸãã
Scinai Immunotherapeutics Ltdã®æ倧ã®åçæºã¯äœã§ããïŒ
î--ã«ãããŠã--éšéãScinai Immunotherapeutics Ltdã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯--ã§ãå
šåçã®--%ãå ããŠããŸãã
